Nucleic acid construct
The nucleic acid construct system with frame slipping and translational read-through motifs addresses the challenges of transgene expression control, achieving precise and safe expression of multiple transgenes, particularly cytokines, by regulating their levels and ratios.
Patent Information
- Application Number
- JP2024159377
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-07-31
- Filing Date
- 2024-09-13
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2039-07-31
AI Technical Summary
Current methods for modulating the expression of multiple transgenes in gene therapy face challenges such as promoter interference, unpredictable expression ratios, and limitations in controlling the relative expression of transgenes, especially when expressing cytokines or toxins, which can be toxic at high levels.
A nucleic acid construct system using frame slipping or translational read-through motifs to control the relative expression of two or more transgenes from a single mRNA transcript, allowing for precise regulation of transgene expression levels, including the use of cleavage sites and specific nucleotide sequences to achieve desired expression ratios.
Enables precise and predictable expression of transgenes, including cytokines like IL-12, at significantly lower levels than previous methods, reducing toxicity and enabling safe therapeutic applications.
Smart Images

Figure 2024169492000013 
Figure 2024169492000014 
Figure 2024169492000015
Abstract
Description
[Technical field]
[0001] The present invention relates to constructs and methods for modulating the relative expression of a transgene. [Background technology]
[0002] Expression of multiple transgenes Gene therapy involves modifying cells to express biomolecules to treat or correct a pathological condition. Obtaining physiological or therapeutically relevant levels of either a biomolecule is important for successful gene therapy.
[0003] Current methods for modulating gene expression generally rely on modifying promoter regions to increase or decrease the rate of transcription or inserting regulatory elements into them to make their expression inducible through the action of engineered transcription factors and small molecules.
[0004] Gene therapy approaches often involve the expression of more than one transgene. Transducing cells with multiple vectors to produce multiple products is difficult, expensive, and unpredictable. For this reason, various methods have been developed to allow the co-expression of two proteins from a single vector (see Figure 1).
[0005] Initial attempts used two different promoters in the same cassette, which results in two separate transcripts, each encoding a separate protein. This is a challenging approach for many reasons. A key problem is "promoter interference," where the first promoter dominates and causes silencing of the second promoter. In addition, different promoters function differently in different cellular contexts, which makes consistent "tuning" of the relative expression of each transgene difficult to achieve.
[0006] An alternative approach is to use an internal ribosome entry sequence (IRES). Here, a single transcript is generated. The IRES sequence in the transcript is placed between the open reading frames of the two transgenes, mimicking the mRNA cap structure. Thus, the ribosome will initiate translation at either the 5' cap or the IRES, resulting in the expression of two separate proteins. An important limitation of this method is the inability to control relative expression. The 3' transcript is typically expressed lower than the 5' one, but the ratio of expression is difficult to predict and adjust.
[0007] Further approaches were developed after elucidating the role of the FMDV 2A peptide, which allows Foot and Mouth Disease Virus (FMDV) (and related viruses) to express multiple proteins from a single open reading frame (ORF) (Donnelly et al., J. Gen. Virol.; 82, 1027-1041 (2001)). The 2A peptide (and homologues) is cleaved with very high efficiency immediately after translation of the ORF, allowing expression of multiple peptides from a single ORF. Use of a self-cleaving peptide such as the 2A peptide results in expression of transgenes at a 1:1 ratio.
[0008] WO 2016 / 174409 describes the use of modified signal peptides to vary the ratio of transgene expression in nucleic acid constructs.In this system, mutations are introduced, for example, into the signal peptide motif of type I transmembrane protein to reduce the efficiency of transport to cell surface.This approach allows the expression level of cell surface to be reduced by about 10 times compared to wild-type signal peptide motif.
[0009] However, this strategy works by reducing the trafficking of proteins to the cell surface and is therefore only suitable for reducing the expression of cell surface proteins, and a 10-fold reduction in expression may not be sufficient for some applications, such as the expression of toxic compounds whose overexpression can result in the death of the host cell.
[0010] Thus, there is a need for alternative approaches for altering the relative expression of two or more transgenes in a cell that do not suffer from these limitations.
[0011] Chimeric antigen receptors (CARs) Chimeric antigen receptor T cell (CAR-T cell) therapy redirects cytolytic T cells to target tumor cells through the expression of chimeric antigen receptors (CARs) that recognize tumor-specific antigens on the cell surface. Chimeric antigen receptors consist of an antibody or ligand binding motif, a spacer domain and a transmembrane domain fused to the intracellular signaling domain from the CD3ζ chain of the T cell receptor (TCR). Signaling domains from co-receptors such as CD28, OX40 or 4-1BB can also be included in CAR1 along with the CD3ζ signaling domain.
[0012] CAR-T cell therapy has demonstrated itself as an effective treatment for hematological malignancies such as B-cell leukemia, achieving impressive response rates. However, CAR-T cell therapy has not been able to achieve the same success in the treatment of solid tumors, where many factors combine to limit CAR-T cell activity. These include expression of immunosuppressive ligands such as PD-L1, secretion of cytokines that mitigate favorable inflammatory responses, expression of ligands that induce apoptosis by tumor cells, and nutrient deprivation. To overcome the immunosuppressive tumor microenvironment, CAR-T cells have been engineered to express molecules that block immunosuppressive signaling or allow T cells to survive in an unfavorable tumor microenvironment.
[0013] Cytokines that enhance inflammatory responses may increase the efficacy of CAR-T cell therapy. These include IL-7, IL-12, IL15, IL-17A, IL-18, and IL-21, which have been shown to enhance CAR-T cell responses when provided exogenously or released during CAR-T cell therapy.
[0014] IL-12 is a potent immunomodulatory cytokine, normally secreted by phagocytes and dendritic cells in response to T and natural killer (NK) cell signals; as well as extracellular matrix components. CAR-T cells have been engineered to express IL-12 from constitutive or inducible promoters, which has been shown to improve the efficacy of CAR-T cell therapy when targeting solid tumors. Because IL-12 is systemically toxic, CAR cells or other immune cells have been engineered to release IL-12 into the tumor microenvironment. However, IL-12 secretion by transgenic T cells can result in highly toxic systemic levels.
[0015] Expression of cytokines, chemokines or toxins may improve the efficacy of CAR-T cell therapy, but secretion of these biomolecules must be tightly regulated to limit toxicity within safe levels that provide therapeutic benefit and minimal side effects. This can be accomplished by modulating the rate of gene transcription from the promoter region by inserting or deleting cis-acting sequences to obtain the desired level of transcription or by introducing inducible elements into the promoter region. Notable inducible promoter systems include the tetracycline-off and tetracycline-off systems, which utilize the tetracycline response element (TRE) in conjunction with an engineered form of the tetracycline repressor protein (TetR) that binds to a 19-bp nucleotide sequence of TRE2. In the tetracycline-off system, TetR is fused to the transactivation domain of virion protein 16 (VP16) from herpes simplex virus to generate the tetracycline transactivator (tTA). In the absence of tetracycline, tTA binds to the TRE in the promoter region and enhances gene transcription; conversely, in the presence of tetracycline, tTA cannot bind to the TRE and transcription does not occur. A reverse tTA (rtTA) and tetracycline on system was created by mutating the TetR domain in tTA to make it tetracycline dependent for binding to the TRE. In the presence of tetracycline, rtTA can bind to the TRE and stimulate transcription, but not in its absence. Although the tetracycline inducible system allows for control of transgene expression, it relies on the use of small molecules, the insertion of a TRE into the promoter sequence, and the expression of either tTA or rtTA to do so, placing a great burden on the cell.
[0016] An alternative approach to control gene expression is to use an internal ribosome entry site (IRES). As explained above, an IRES is placed downstream of a primary transgene and promotes constitutive expression of additional transgenes, usually at a lower level than the primary transgene. To enhance immune responses and avoid the need for preconditioning of the host before infusion of CAR-T cells, such an approach has been used to constitutively express IL-12 in CAR-T cells. However, the expression level of IL-12 is unpredictable and can still be toxic in vivo.
[0017] Therefore, there is a need for alternative methods for co-expressing chimeric antigen receptors with molecules, such as cytokines, chemokines or toxins, that are not associated with the above-mentioned disadvantages. Summary of the Invention [Means for solving the problem]
[0018] The present inventors have developed a system that uses frame-slip or translational read-through as a means to modulate transgene expression. In particular, the system can be used to control the relative expression of two or more transgenes expressed from a single mRNA transcript.
[0019] Thus, in a first aspect, the present invention provides a nucleic acid construct comprising a first nucleotide sequence of interest (NOI1); a frame slip motif or translational read-through motif (FSM / TRM); and a second nucleotide sequence of interest (NOI2).
[0020] The nucleic acid construct may also include a nucleotide sequence encoding a cleavage site (CL) such that NOI1 and NOI2 are expressed as separate proteins.
[0021] The nucleic acid construct has the structure: NOI1-FSM / TRM-CL-NOI2 or NOI1-CL-FSM / TRM-NOI2 may include.
[0022] In particular, the nucleic acid construct has the structure: NOI1-CL-FSM-NOI2; or NOI1-TRM-CL-NOI2 Includes.
[0023] A nucleic acid construct may contain more than two nucleotide sequences of interest. For example, a nucleic acid construct may have the structure: NOI1-FSM1 / TRM1-CL1-NOI2-FSM2 / TRM2-CL2-NOI3, or NOI1-CL1-FSM1 / TRM1-NOI2-CL2-FSM2 / TRM2-NOI3 (where: NOI1, NOI2 and NOI3 are nucleotide sequences of interest; FSM1 / TRM1 and FSM2 / TRM2 may be the same or different and are a frame-slip motif or a translational read-through motif; and CL1 and CL2 may be the same or different, each being a nucleic acid sequence encoding a cleavage site. may have:
[0024] A frame-slip motif (FSM) may contain repeats of uracil, thymine or guanine bases, for example the sequence UUUUUUU (SEQ ID NO:1).
[0025] The frame slip motif may also include a stop codon. For example, FSM may have the following sequence: UUUUUUUGA (SEQ ID NO:2) UUUUUUUAG (SEQ ID NO:3) UUUUUUUAA (SEQ ID NO:4) may include one of the following:
[0026] A translational read-through motif (TRM) can include the sequence STOP-CUAG or STOP-CAAUUA, where "STOP" is a stop codon. For example, a translational read-through motif can include the following sequence: UGA-CUAG (SEQ ID NO:5) UAG-CUAG (SEQ ID NO: 6) UAA-CUAG (SEQ ID NO: 7) UGA-CAAUUA (SEQ ID NO: 8) UAG-CAAUUA (SEQ ID NO: 9) UAA-CAAUUA (SEQ ID NO: 10) may include one of the following:
[0027] A nucleic acid construct containing a translational readthrough motif can contain two flanking TRMs, which may be the same or different.
[0028] A nucleic acid construct containing a translational read-through motif can include two nucleic acid sequences, each encoding a cleavage site. A TRM can be located between the two cleavage site-encoding sequences, or there can be two TRMs, each located upstream of a cleavage site.
[0029] A nucleic acid construct containing a translational readthrough motif may contain an attenuated or inefficient signal peptide located upstream of the second (or subsequent) nucleotide of interest.
[0030] A nucleic acid construct comprising a translational read-through motif has the following structure: NOI1-TRM-CL-NOI2 NOI1-TRM1-TRM2-CL-NOI2 NOI1-CL1-TRM-CL2-NOI2 NOI1-TRM-CL-SP-NOI2 NOI1-TRM1-CL1-NOI2-TRM2-CL2-NOI3 NOI1-TRM1-CL1-TRM2-CL2-NOI2 (where: TRM1 and TRM2 may be the same or different and are the first and second translational read-through motifs; CL1 and CL2 may be the same or different and are a first and a second nucleic acid sequence encoding a cleavage site, SP is the attenuated signal peptide; and NOI3 is a third nucleotide sequence of interest. The embodiment may have one of the following:
[0031] The cleavage site may comprise, for example, an autocleaving peptide, a furin cleavage site, or a tobacco etch virus cleavage site.
[0032] The cleavage site may include, for example, the 2A self-cleaving peptide or a 2A-like peptide from an aphthovirus or cardiovirus.
[0033] The second (or subsequent) nucleotide of interest may encode a cytokine, chemokine, or toxin.
[0034] The nucleic acid construct, when expressed in a cell, produces two products: a) a first product encoded by NOI1 alone; and b) a second product encoded by NOI1 and NOI2, which is produced if frame slippage or translational read-through occurs. The polypeptide may be capable of producing
[0035] In this embodiment, the second product may be a chimeric antigen receptor (CAR) and the first product may be a truncated version of the CAR that is unable to induce CAR-mediated cell transduction.
[0036] Alternatively, the first product can be a chimeric antigen receptor (CAR) that includes an intracellular signaling domain (i.e., a first generation CAR), and the second product is a CAR that includes an intracellular signaling domain and one or more costimulatory domains (i.e., a second or third generation CAR).
[0037] In a second aspect, the present invention provides a vector comprising a nucleic acid construct according to the first aspect of the invention.
[0038] The vector can be, for example, a retroviral or lentiviral vector.
[0039] In a third aspect, the present invention provides a cell comprising a nucleic acid construct according to the first aspect of the invention or a vector according to the second aspect of the invention.
[0040] In a fourth aspect, the present invention provides a method for producing a cell according to the third aspect of the invention, the method comprising introducing a nucleic acid construct according to the first aspect of the invention or a vector according to the second aspect of the invention into a cell.
[0041] In a fifth aspect, there is provided a method for modulating the relative expression of two transgenes in a nucleic acid construct, the method comprising including a frame-slip or translational read-through motif between the two transgenes to reduce expression of the downstream transgene.
[0042] An important advantage of using frame-slipping or translational read-through as a means of controlling transgene expression is that a wide range of expression is achievable, and when two transgenes are expressed, the expression level of the second transgene can be reduced to less than 1% of the first transgene, which is significantly lower than the levels that can be achieved using modified signal peptides, making it possible to use the technique for the expression of proteins such as toxic compounds where very low levels of expression are essential.
[0043] The use of frame-slipping or translational read-through allows expression of transgenes at a predictable and defined ratio. By using different frame-slipping or read-through motifs, it is also possible to tune the level of transgene expression.
[0044] This system can be used to control the expression of any transgene and is not limited to the expression of cell surface proteins. In certain embodiments, for example, the following items are provided: (Item 1) A nucleic acid construct comprising a first nucleotide sequence of interest (NOI1); a frame slip motif (FSM) or a translational read-through motif (TRM); and a second nucleotide sequence of interest (NOI2). (Item 2) 2. The nucleic acid construct of item 1, further comprising a nucleotide sequence encoding a cleavage site (CL) such that NOI1 and NOI2 are expressed as separate proteins. (Item 3) structure: NOI1-CL-FSM-NOI2; or NOI1-TRM-CL-NOI2 3. The nucleic acid construct according to Item 2, comprising: (Item 4) 4. The nucleic acid construct according to any one of items 1 to 3, comprising a frame-slip motif (FSM) comprising repeats of uracil, thymine or guanine bases. (Item 5) Item 6. The nucleic acid construct according to item 4, wherein the FSM comprises the sequence UUUUUUU (SEQ ID NO: 1). 6. The nucleic acid construct of item 4 or 5, wherein the FSM also comprises a stop codon. (Item 7) The FSM has the following sequence: UUUUUUUGA (SEQ ID NO:2) UUUUUUUAG (SEQ ID NO:3) UUUUUUUAA (SEQ ID NO:4) 7. The nucleic acid construct according to item 6, comprising one of the following: (Item 8) 4. The nucleic acid construct according to any one of items 1 to 3, comprising a translational read-through motif (TRM) comprising the sequence STOP-CUAG or STOP-CAAUUA (wherein "STOP" is a stop codon). (Item 9) The translational read-through motif has the following sequence: UGA-CUAG (SEQ ID NO:5) UAG-CUAG (SEQ ID NO: 6) UAA-CUAG (SEQ ID NO: 7) UGA-CAAUUA (SEQ ID NO: 8) UAG-CAAUUA (SEQ ID NO: 9) UAA-CAAUUA (SEQ ID NO: 10) 9. The nucleic acid construct according to item 8, comprising one of the following: (Item 10) structure: NOI1-TRM-CL-NOI2 NOI1-TRM1-TRM2-CL-NOI2 NOI1-CL1-TRM-CL2-NOI2 NOI1-TRM-CL-SP-NOI2 NOI1-TRM1-CL1-NOI2-TRM2-CL2-NOI3 NOI1-TRM1-CL1-TRM2-CL2-NOI2 (where: TRM1 and TRM2 may be the same or different and are the first and second translational read-through motifs; CL1 and CL2 may be the same or different and are a first and a second nucleic acid sequence encoding a cleavage site, respectively; SP is the attenuated signal peptide; and NOI3 is a third nucleotide sequence of interest. 10. The nucleic acid construct according to item 8 or 9, comprising: (Item 11) 11. The nucleic acid construct according to any one of items 2 to 10, wherein the cleavage site comprises a self-cleaving peptide, a furin cleavage site, or a tobacco etch virus cleavage site. (Item 12) 12. The nucleic acid construct of claim 11, wherein the cleavage site comprises a 2A self-cleaving peptide or a 2A-like peptide derived from an aphthovirus or a cardiovirus. (Item 13) 13. A nucleic acid construct according to any of items 1 to 12, wherein NOI2 encodes a cytokine, chemokine or toxin. (Item 14) When expressed in cells, it produces two products: a) a first product encoded by NOI1 alone; and b) a second product encoded by NOI1 and NOI2, which is produced if frame slippage or translational read-through occurs. The nucleic acid construct according to item 1, which is capable of producing (Item 15) 15. The nucleic acid construct of item 14, wherein the second product is a chimeric antigen receptor (CAR) and the first product is a truncated version of the CAR that is unable to induce CAR-mediated cell signaling. (Item 16) 15. The nucleic acid construct of claim 14, wherein the first product is a chimeric antigen receptor (CAR) comprising an intracellular signaling domain and the second product is a CAR comprising an intracellular signaling domain and one or more costimulatory domains. (Item 17) 17. A vector comprising the nucleic acid construct according to any one of items 1 to 16. (Item 18) 18. The retroviral or lentiviral vector of item 17. (Item 19) A cell comprising the nucleic acid construct according to any one of items 1 to 16 or the vector according to item 17 or 19. (Item 20) 20. A method for producing the cell according to item 19, comprising the step of introducing into a cell the nucleic acid construct according to any one of items 1 to 16 or the vector according to item 17 or 18. (Item 21) A method for modulating the relative expression of two introduced genes in a nucleic acid construct, comprising the step of including a frame-slip or translational read-through motif between the two introduced genes to reduce expression of the downstream introduced gene. [Brief description of the drawings]
[0045] [Figure 1]Methods utilized to express different proteins from the same vector: (a) Two different promoters in the same cassette result in two different transcripts, each giving rise to a separate protein. (b) The use of an internal ribosome entry sequence (IRES) results in a single transcript that is translated into two separate proteins. (c) The use of the FMDV2A peptide results in a single transcript and a single polyprotein that is rapidly cleaved into two separate proteins. [Diagram 2] Frameslip motif and construct design. (A) Diagram showing the frameslip motif, where a series of seven uridines was inserted into the transgene sequence to promote frame slipping. Frame slipping results in continued transcription / translation of the alternative reading frame, normally in the -1 orientation, and the production of a functional protein. (B) Structure of the construct showing the location of the transgene, the frameslip motif (SLIP) and the 2A self-cleaving peptide sequence. (C) Flow cytometric analysis of SupT1 cells transduced with constructs containing the RQR8 sorting selectable marker followed by a CD22-CD19 chimeric protein consisting of either a regulatory sequence (6xU) or a frameslip motif (7xU) and the ectodomain of CD22 fused to the transmembrane and truncated endodomains of CD19. Introduction of the frameslip motif resulted in a dramatic decrease in expression of the CD22-CD19 chimera with similar levels of the RQR8 sorting selectable marker observed. [Diagram 3]Translational read-through motifs and construct design. (A) Examples of known translational read-through motifs. (B-G) Structures of translational read-through motif constructs. (B) Translational read-through constructs consisting of two transgenes with a translational read-through motif placed 3' of the first transgene and a 2A self-cleaving peptide sequence and 5' of transgene 2. Expression of transgene 1 is significantly higher than transgene 2. (B') A double-stop translational read-through construct incorporating two stop codons into the translational read-through motif to further reduce expression levels beyond those achieved with a single stop codon. (C) A universal translational read-through construct consisting of a translational read-through motif flanked by two 2A self-cleaving peptide sequences. This construct mitigates sequence-dependent effects that may result in unpredictable levels of translational read-through. (D) A combinatorial approach combining a translational read-through motif with an attenuated signal peptide sequence to further reduce expression levels of transgene 2. (E and E') Composite translational read-through motifs with multiple motifs arranged in tandem to produce a cascade of reduced transgene expression. (E) A translational read-through motif and a 2A self-cleaving peptide sequence are used to express multiple transgenes from a single cassette. (E') A self-cleaving peptide sequence is used to separate the translational read-through motif 5' of transgene 2. (F and F') Functional translational read-through constructs. (F) Secretion of the antigen binding domain (scFv / VHH) and functional CAR can be achieved by placing a translational read-through motif 3' of the spacer domain of the CAR. Functional read-through results in expression of a functional CAR, and termination of translation at a stop codon results in a secreted antibody. (F') A combination of first, second and third generation CARs can be produced by placing a translational read-through motif 3' of the first endodomain (either the CD3ζ endodomain or the co-receptor endodomain). Functional translational read-through switches expression from the first generation CAR to the second or third generation CAR. [Figure 4A]Comparison of attenuated signal peptide and translational read-through motif approaches to control expression of CD22-CD19 chimeras. (A) Flow cytometry analysis of HEK293T cells transfected with constructs encoding the RQR8 sorting selectable marker and CD22-CD19 chimeras. Signal peptide mutants (line 1), translational read-through motif constructs (lines 2 and 3) and double-stop translational read-through motif (line 4). Compared to the wild-type signal peptide, expression of the CD22-CD19 chimera is reduced with the lysine 11 signal peptide mutant (L11K mutation). The stop-CUAG and stop-CAAUUA translational read-through motifs yield similar results when they are placed 5' to the CD22-CD19 transgene, with both motifs reducing the expression level of the chimera to approximately 2% or less of the RQR8 sorting selectable marker. Lower expression levels of the CD22-CD19 chimera were obtained using the double-stop translational read-through motif (line 4). (B) Quantification of the mean fluorescence intensity of CD22-CD19 chimeras on the surface of transfected HEK293T cells comparing the attenuated signal peptide mutant with a translational read-through construct. Using the translational read-through construct, substantially lower levels of CD22-CD19 chimeras were obtained compared to the attenuated signal peptide mutant. [Figure 4B]Comparison of attenuated signal peptide and translational read-through motif approaches to control expression of CD22-CD19 chimeras. (A) Flow cytometry analysis of HEK293T cells transfected with constructs encoding the RQR8 sorting selectable marker and CD22-CD19 chimeras. Signal peptide mutants (line 1), translational read-through motif constructs (lines 2 and 3) and double-stop translational read-through motif (line 4). Compared to the wild-type signal peptide, expression of the CD22-CD19 chimera is reduced with the lysine 11 signal peptide mutant (L11K mutation). The stop-CUAG and stop-CAAUUA translational read-through motifs yield similar results when they are placed 5' to the CD22-CD19 transgene, with both motifs reducing the expression level of the chimera to approximately 2% or less of the RQR8 sorting selectable marker. Lower expression levels of the CD22-CD19 chimera were obtained using the double-stop translational read-through motif (line 4). (B) Quantification of the mean fluorescence intensity of CD22-CD19 chimeras on the surface of transfected HEK293T cells comparing the attenuated signal peptide mutant with a translational read-through construct. Using the translational read-through construct, substantially lower levels of CD22-CD19 chimeras were obtained compared to the attenuated signal peptide mutant. [Figure 5-1]Tandem translational read-through motif. A) Diagram of constructs generated with tandemly arranged stop codons and translational read-through motifs. For simplicity, only four examples showing the structure of constructs with tandem translational read-through motifs are shown. The cell surface marker, an HA epitope presented on the CD8a stalk, is always in the first position in the cassette, followed by either tandem Clover3 or EBFP with different coding sequences, separated by a self-cleaving peptide sequence (2A). Two control constructs were cloned in which the stop codon was replaced by UGG (encoding tryptophan) and the tandem mClover or EBFP was in the second or third position. For constructs with tandem translational read-through motifs, all three stop codons (UGA, UAG and UAA) were tested and the translational read-through motif utilized was CUAG. The same stop codon was used in both positions. B) Flow cytometry of construct-transduced PBMCs shows tandem Clover3 fluorescence intensity from constructs with 0, 1 or 2 stop codons / translational read-through motifs (control is no stop codon and tandem Clover3 at position 2). Histograms show reduced tandem Clover3 expression from constructs with tandem translational read-through motifs, with levels varying depending on the stop codon present. C) Normalization of tandem Clover3 fluorescence intensity levels relative to cell surface markers. When placed immediately downstream of a UGA, UAG or UAA stop codon and a CUAG translational read-through motif, levels were reduced 6-, 24- or 33-fold, respectively. A 100-fold reduction in tandem Clover3 levels was observed when the tandem Clover3 sequence was placed downstream of two stop codons and a translational read-through motif. [Figure 5-2]Tandem translational read-through motif. A) Diagram of constructs generated with tandemly arranged stop codons and translational read-through motifs. For simplicity, only four examples showing the structure of constructs with tandem translational read-through motifs are shown. The cell surface marker, an HA epitope presented on the CD8a stalk, is always in the first position in the cassette, followed by either tandem Clover3 or EBFP with different coding sequences, separated by a self-cleaving peptide sequence (2A). Two control constructs were cloned in which the stop codon was replaced by UGG (encoding tryptophan) and the tandem mClover or EBFP was in the second or third position. For constructs with tandem translational read-through motifs, all three stop codons (UGA, UAG and UAA) were tested and the translational read-through motif utilized was CUAG. The same stop codon was used in both positions. B) Flow cytometry of construct-transduced PBMCs shows tandem Clover3 fluorescence intensity from constructs with 0, 1 or 2 stop codons / translational read-through motifs (control is no stop codon and tandem Clover3 at position 2). Histograms show reduced tandem Clover3 expression from constructs with tandem translational read-through motifs, with levels varying depending on the stop codon present. C) Normalization of tandem Clover3 fluorescence intensity levels relative to cell surface markers. When placed immediately downstream of a UGA, UAG or UAA stop codon and a CUAG translational read-through motif, levels were reduced 6-, 24- or 33-fold, respectively. A 100-fold reduction in tandem Clover3 levels was observed when the tandem Clover3 sequence was placed downstream of two stop codons and a translational read-through motif. [Figure 6-1]Controlled expression of human flexi-IL-12 downstream of a translational read-through motif. A) Diagram showing the structure of the construct in which human flexi-IL-12, consisting of a fusion between the IL-12α (p35) and IL-12β (p40) subunits, was placed downstream of the sortable selection marker RQR8 with a self-cleaving peptide facilitating expression of both proteins. All three stop codons were tested using the translational read-through motif CAAUUA. B) Representative flow cytometry plots of PBMCs transduced with the constructs and stained with antibodies against CD3ε and RQR8. C) Quantification of secreted IL-12 from transduced PBMCs 24, 48 and 72 hours after determination of transduction efficiency. The results demonstrate that the translational read-through construct significantly reduces IL-12 secretion. [Figure 6-2] Controlled expression of human flexi-IL-12 downstream of a translational read-through motif. A) Diagram showing the structure of the construct in which human flexi-IL-12, consisting of a fusion between the IL-12α (p35) and IL-12β (p40) subunits, was placed downstream of the sortable selection marker RQR8 with a self-cleaving peptide facilitating expression of both proteins. All three stop codons were tested using the translational read-through motif CAAUUA. B) Representative flow cytometry plots of PBMCs transduced with the constructs and stained with antibodies against CD3ε and RQR8. C) Quantification of secreted IL-12 from transduced PBMCs 24, 48 and 72 hours after determination of transduction efficiency. The results demonstrate that the translational read-through construct significantly reduces IL-12 secretion. [Figure 7-1]Controlled expression of mouse IL-12 downstream of a translational read-through motif. A) Diagram of a tricistronic construct carrying a suicide gene (RapaCasp9), cell surface marker Thy1.1 and mouse flexi-IL-12. Mouse flexi-IL-12 levels were modulated by an internal ribosome entry site (IRES), an attenuated signal peptide motif or a translational read-through motif. B) Representative flow cytometry plots of BalbC splenocytes transduced with the constructs and stained with antibodies against CD3 and Thy1.1. C) Quantification by ELISA of secreted IL-12 levels from transduced splenocytes. D) Supernatants from transduced splenocytes were used to restimulate activated splenocytes. Supernatants from restimulation were analyzed for the presence of IFNg by ELISA. Importantly, these results demonstrated that supernatants from splenocytes transduced with a translational read-through motif were able to induce IFNγ secretion from restimulated splenocytes. [Figure 7-2] Controlled expression of mouse IL-12 downstream of a translational read-through motif. A) Diagram of a tricistronic construct carrying a suicide gene (RapaCasp9), cell surface marker Thy1.1 and mouse flexi-IL-12. Mouse flexi-IL-12 levels were modulated by an internal ribosome entry site (IRES), an attenuated signal peptide motif or a translational read-through motif. B) Representative flow cytometry plots of BalbC splenocytes transduced with the constructs and stained with antibodies against CD3 and Thy1.1. C) Quantification by ELISA of secreted IL-12 levels from transduced splenocytes. D) Supernatants from transduced splenocytes were used to restimulate activated splenocytes. Supernatants from restimulation were analyzed for the presence of IFNg by ELISA. Importantly, these results demonstrated that supernatants from splenocytes transduced with a translational read-through motif were able to induce IFNγ secretion from restimulated splenocytes. [Figure 8A]Toxicity test of translational read-through IL-12 construct. A) Splenocytes were co-transduced with the RapaCasp6, Thy1.1 and IL-12 coding construct and a second construct containing truncated mouse CD34 (mudCD34), firefly luciferase (FLuc) and anti-GD2 chimeric antigen receptor (CAR). Transduced splenocytes were stained with antibodies against CD34 and Thy1.1 and flow cytometry was performed to determine transduction efficiency. B) Transduced splenocytes were injected into mice, and 15 days later, they were sacrificed and their spleens were removed. Spleen enlargement was observed only in mice injected with splenocytes transduced with constitutively expressed IL-12 (group indicated as 2A). [Figure 8B] Toxicity test of translational read-through IL-12 construct. A) Splenocytes were co-transduced with the RapaCasp6, Thy1.1 and IL-12 coding construct and a second construct containing truncated mouse CD34 (mudCD34), firefly luciferase (FLuc) and anti-GD2 chimeric antigen receptor (CAR). Transduced splenocytes were stained with antibodies against CD34 and Thy1.1 and flow cytometry was performed to determine transduction efficiency. B) Transduced splenocytes were injected into mice, and 15 days later, they were sacrificed and their spleens were removed. Spleen enlargement was observed only in mice injected with splenocytes transduced with constitutively expressed IL-12 (group indicated as 2A). [Figure 9-1] Flow cytometric analysis of splenocytes. A) Splenocytes from sacrificed mice were stained with antibodies against CD11b, CD3, CD4, CD8 and CD19 and analyzed by flow cytometry. The gating strategy used is indicated. B-F) Percentage of CD11b+ (macrophages), CD3+ (T cells), CD4+ (helper T cells), CD8+ (cytotoxic T cells) and C19+ (B cells) present. In the spleens of mice injected with splenocytes transduced with constructs constitutively expressing IL-12 or IRES, increased numbers of macrophages and T cells were present. A reduced number of B cells was observed in mice with splenocytes constitutively expressing IL-12. [Figure 9-2]Flow cytometric analysis of splenocytes. A) Splenocytes from sacrificed mice were stained with antibodies against CD11b, CD3, CD4, CD8 and CD19 and analyzed by flow cytometry. The gating strategy used is indicated. B-F) Percentage of CD11b+ (macrophages), CD3+ (T cells), CD4+ (helper T cells), CD8+ (cytotoxic T cells) and C19+ (B cells) present. In the spleens of mice injected with splenocytes transduced with constructs constitutively expressing IL-12 or IRES, increased numbers of macrophages and T cells were present. A reduced number of B cells was observed in mice with splenocytes constitutively expressing IL-12. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0046] The present invention relates to nucleic acid constructs that contain motifs that reduce expression of a transgene, such as frameslip motifs or translational readthrough motifs.
[0047] Frame slip During transcription, RNA polymerase catalyzes the incorporation of nucleotides into a growing RNA strand based on complementarity to a DNA template. However, slippage or "stuttering" can occur when RNA polymerase encounters a stretch of repeat bases. Transcriptional slippage is utilized in nature, for example, to regulate the E. coli pyrBI and codBA operons, to express the P gene in paramyxoviruses, and to decode the cellular dnaX gene in Thermus thermophiles.
[0048] When RNA polymerase slips, one (or perhaps two) of the repeat bases is missing, which can result in the synthesis of an mRNA encoding an alternative reading frame.
[0049] A nucleic acid construct of the invention may contain a transcriptional frame slippage site such that transcription of a downstream transgene occurs only in the presence of RNA polymerase slippage resulting in an mRNA encoding an alternative reading frame.
[0050] Translation of an mRNA sequence into a protein is a complex process that involves the orchestration of ribosomes, initiation and elongation factors, aminoacyl-transfer RNAs (aa-tRNAs), aminoacyl-tRNA synthetases, and termination factors. Initiation of translation begins when a complex of factors binds to the 5' end of the mRNA, which then leads to the recruitment of a 40S ribosome and scanning of the mRNA. When the initiation factor-40S ribosome complex encounters a codon (a triplet of nucleotides) that codes for the amino acid methionine (AUG codon), the 60S ribosome is recruited and polypeptide synthesis begins with the pairing of a cognate tRNA loaded with the appropriate amino acid. Initiation of translation can occur at alternative initiation codons other than AUG, but AUG is the most frequently used initiation codon. Elongation of a polypeptide occurs in a cyclical manner in which a tRNA binds to its cognate codon, a peptide bond forms between the newly added amino acid and the elongating polypeptide, and the polypeptide moves to expose the next codon.
[0051] During translation, ribosome pausing can occur where the ribosome stops at a particular codon. Ribosome pausing can promote degradation of the mRNA by the nucleocytic pathway or it can induce slippage in the -1 or -2 direction. Repeated sequences within mRNA, such as UUUUUUA, are known to induce translation frame slipping, and this sequence is present at the 3' end of the group-specific antigen gene (gag) and polymerase (pol) gene of human immunodeficiency virus (HIV). Translation frame slipping -1 of the HIV gag / pol gene results in the expression of the Gag-Pol polyprotein.
[0052] A nucleic acid construct of the invention may contain a translational frame-slipping site, such that translation of a downstream transcript occurs only in the presence of ribosomal frame-slipping.
[0053] The frameslip site may contain a stretch of bases of the same type.
[0054] The frame-slip motif may be located upstream and / or downstream of the cleavage site in the nucleic acid construct. The frame-slip motif is located between the first and second transgenes in the nucleic acid construct.
[0055] The frame-slip motif may be used alone. In this embodiment, a second transgene may be placed out of frame downstream of the frame-slipping site such that frame-slipping is required for transcription or translation of the second transgene.
[0056] A motif may, for example, comprise a stretch of 5, 7, 8, 10 or 11 bases. A site may, for example, comprise repeats of uracil, adenosine or guanine bases. A site may, for example, comprise the sequence shown as SEQ ID NO:1. UUUUUUU (sequence number 1).
[0057] Alternatively, a frame slip site may be used in combination with a stop codon. In this embodiment, the stop codon is located in frame downstream of the frame slip site such that frame slipping is necessary for the stop codon to be ignored.
[0058] The stop codon can be UGA, UAG, or UAA. The frame slip site can include repeats of uracil, adenosine, or guanine bases in multiples of three, such as 3, 6, or 9 repeats of uracil, adenosine, or guanine bases.
[0059] Examples of frame slip site / stop codon combinations are shown as SEQ ID NOs:2, 3 and 4. UUUUUUUGA (SEQ ID NO:2) UUUUUUUAG (SEQ ID NO:3) UUUUUUUAA (sequence number 4).
[0060] Translation Read-Through Translation terminates when a ribosome encounters a UGA, UAG, or UAA stop codon. At this point, a release factor recognizes the stop codon and facilitates the release and recycling of the ribosome. Because competition between release factors and near-cognate tRNAs and continued elongation of the polypeptide occurs at a rate of only 0.1%, translation termination usually occurs with high fidelity by recoding the stop codon. However, elevated levels of recoding of the stop codon resulting in translational read-through have been reported in certain genes. In some cases, this has led to the generation of longer polypeptides with additional functional motifs, a process referred to as functional read-through.
[0061] Translational read-through occurs when release factor 1 (RF1) fails to recognize a stop codon and a near-cognate aa-tRNA inserts an amino acid into the elongating polypeptide, thereby suppressing the stop codon. The local concentrations of release factors and aa-tRNAs affect the level of stop codon suppression and translational read-through, with low concentrations of release factors promoting translational read-through. In mammals, suppression of the UAG stop codon results in the insertion of a tryptophan, arginine or cysteine residue.
[0062] One of the earliest examples of stop codon suppression was the rabbit beta globin gene, in which translational readthrough resulted in the addition of 22 amino acids to the C-terminus of protein 3.
[0063] The frequency of translational read-through depends on many factors, including: 1) the stop codon used (UGA, UAG, or UAA); 2) the sequences immediately adjacent to the stop codon (the six nucleotides upstream and downstream of the stop codon are particularly important); and 3) the presence of cis-acting sequences at the 3' end of the mRNA.
[0064] The three stop codons vary in termination efficiency, with UAA being the strongest stop codon and UGA being the weakest, and a hierarchy of termination efficiency is defined as UAA>UAG>UGA, such that the highest level of translational readthrough is exhibited by the UGA stop codon and the lowest by the UAA stop codon.
[0065] Sequence analysis of genes that exhibit translational readthrough has identified at least two distinct motifs that promote stop codon suppression and sustained translation: STOP-CUAG and STOP-CAAUUA (where stop can be UGA, UAG, or UAA). The level of translational readthrough depends on the stop codon used: UGA evidences the highest level of translational readthrough, with decreasing levels of readthrough obtained from UAG and UAA stop codons, such that the overall hierarchy of readthrough is UGA>UAG>UAA.
[0066] The nucleic acid construct of the present invention may comprise one of the sequences shown as SEQ ID NOs: 5 to 10. UGACUAG (SEQ ID NO: 5) UAGCUAG (SEQ ID NO: 6) UAACUAG (SEQ ID NO: 7) UGACAAUUA (SEQ ID NO: 8) UAGCAAUUA (SEQ ID NO: 9) UAACAAUUA (SEQ ID NO: 10)
[0067] The translational read-through site may be located between the first and second transgenes in the nucleic acid construct. The translational read-through site may be located upstream and / or downstream of the cleavage site in the nucleic acid construct. The translational read-through site may be adjacent to the cleavage site (Figure 3C). Two or more translational read-through sites may be used, for example, next to each other (Figure 3B') or adjacent to the cleavage site (Figure E').
[0068] To further reduce the expression level of the downstream transgene, multiple stop codons can be inserted 5' to the translational read-through motif (Figure 2B). An example of a multiple stop translational read-through motif is shown as SEQ ID NO: 11, in which two UGA stop codons are placed 5' to the CUAG read-through motif. UGAUGACUAG (SEQ ID NO: 11)
[0069] If the nucleic acid construct contains more than two transgenes, composite translational readthrough motifs can be placed in tandem 5' to the sequence encoding the cleavage site. This allows multiple transgenes to be expressed at different ratios. With each additional readthrough motif, the expression level should be reduced 10-50 fold compared to the upstream transgene.
[0070] The nucleic acid construct having a composite translational readthrough motif has the structure: NOI1-TRM1-CL1-NOI2-TRM2-CL2-NOI3 may have:
[0071] Readthrough sites can be positioned within a coding sequence such that two versions of the protein are produced: a short version produced by translation of the transcript up to the readthrough site (i.e., where readthrough does not occur), and a longer version produced by translation of the transcript outside and downstream of the readthrough site (i.e., where readthrough does occur). Examples of such positions are shown in Figure 3, F and F'.
[0072] Modified signal peptide Although the translational read-through motif significantly reduces transgene expression, in certain situations, it may be necessary to further reduce expression levels. In the case of type I transmembrane and secretory proteins, further reduction of expression can be achieved by combining a modified signal peptide sequence with a translational read-through motif. Such an approach is suitable for type I transmembrane and secretory proteins with a signal peptide sequence. In this case, a modified signal peptide and a second transgene are placed 3' to the translational read-through motif and the self-cleaving peptide sequence (Figure 3D).
[0073] Signal peptides are short peptides, typically 5-30 amino acids long, present at the N-terminus of most newly synthesized proteins destined for the secretory pathway. These proteins include proteins that reside inside any of the specific organelles (e.g., the endoplasmic reticulum, Golgi, or endosomes) and are secreted from the cell, as well as transmembrane proteins.
[0074] Signal peptides generally contain a core sequence, which is a long stretch of hydrophobic amino acids that tend to form a single alpha helix. Signal peptides may begin with a short stretch of positively charged amino acids, which helps enforce the proper topology of the polypeptide during translocation. At the end of the signal peptide, there is typically a stretch of amino acids that is recognized and cleaved by a signal peptidase. The signal peptidase may cleave either during or after the translocation is completed to generate a free signal peptide and a mature protein. The free signal peptide is then digested by a specific protease.
[0075] Generally, the signal peptide is located at the amino terminus of the molecule, although several carboxy-terminal signal peptides are known.
[0076] Modified signal peptides are described in detail in WO 2016 / 174409, which is incorporated herein by reference. The modified signal peptide may contain one or more mutations, such as substitutions or deletions, such that it has fewer hydrophobic amino acids than the wild-type signal peptide from which it is derived. The term "wild-type" refers to the sequence of the signal peptide present in the natural protein from which it is derived.
[0077] When a nucleic acid construct contains two transgenes that both encode transmembrane proteins, the protein encoded by the downstream transgene (which has a lower relative expression) may contain fewer hydrophobic amino acids than the protein encoded by the upstream transgene (which has a higher relative expression).
[0078] The hydrophobic amino acid mutated to alter signal peptide efficiency can be alanine (A); valine (V); isoleucine (I); leucine (L); methionine (M); phenylalanine (P); tyrosine (Y); or tryptophan (W).
[0079] The modified signal peptide may contain one, two, three, four or five amino acid deletions or substitutions of hydrophobic amino acids. The hydrophobic amino acids may be replaced with non-hydrophobic amino acids, such as hydrophilic or neutral amino acids.
[0080] nucleic acid construct The present invention relates to a nucleic acid construct comprising a first nucleotide sequence of interest (NOI1); a frame-slip motif or translational read-through motif (FSM / TRM); and a second nucleotide sequence of interest (NOI2).
[0081] A "nucleotide of interest" may be RNA or DNA. A nucleotide of interest (NOI) encodes a polypeptide of interest (POI), which may be all or part of a protein.
[0082] NOI1 and NOI2 (optionally together with subsequent NOI(s)) may encode a protein when transcribed and translated together. For example, the nucleic acid construct, when expressed in a cell, produces two products: a) a first product encoded by NOI1 alone; and b) a second product encoded by NOI1 and NOI2, which is produced if frame slippage or translational read-through occurs. The polypeptide may be capable of producing
[0083] The relative expression level of the full length product encoded by NOI1 and NOI2 may be less than the expression level of the truncated product encoded by NOI1 alone.
[0084] Alternatively, the nucleic acid construct may contain one or more cleavage sites such that the nucleotide sequence of interest is expressed as a separate protein.
[0085] The nucleic acid construct of the invention can encode a polyprotein comprising a first and a second polypeptide. The polyprotein can be cleaved at the cleavage site to generate two separate polypeptides.
[0086] The NOI may encode an intracellular, transmembrane or secreted protein.
[0087] The NOI may, for example, comprise a chimeric antigen receptor (CAR) or a part thereof, or an agent, such as a cytokine, that affects the activity of a CAR or a CAR expressing cell. It can be downloaded.
[0088] The transgene can code for a target antigen. In this regard, the technology can be used to produce a variety of target antigens with very low levels of the target antigen. These can be used, for example, in functional assays of T cells expressing CAR or engineered T cell receptors (TCR).
[0089] The NOI may code for a protein involved in the synthesis of another entity by the cell. For example, cells can be induced to express the cancer antigen disialoganglioside (GD2) by transgenic expression of two enzymes: GM3 synthase and GD2 synthase (WO 2015 / 132604). By reducing the expression levels of these enzymes in the cell, GD2 low It is possible to make target cells.
[0090] The NOI may encode a cytokine, such as a cytokine that enhances the inflammatory response and / or increases the efficacy of CAR-T cell therapy. The cytokine may be selected from the following: IL-7, IL-12, IL15, IL-17A, IL-18 and IL-21. In particular, the cytokine may be IL-12.
[0091] Interleukin 12 (IL-12) is an interleukin naturally produced by dendritic cells, macrophages, neutrophils and human B lymphoblast cells in response to antigenic stimulation. IL-12 is involved in the differentiation of naive T cells into Th1 cells. It is known as a T cell stimulatory factor that can stimulate the growth and function of T cells. It stimulates the production of interferon gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) from T cells and natural killer (NK) cells and reduces IL-4-mediated suppression of IFN-γ.
[0092] IL-12 plays an important role in the activity of natural killer cells and T lymphocytes. IL-12 mediates the enhancement of the cytotoxic activity of NK cells and CD8+ cytotoxic T lymphocytes.
[0093] IL-12 is a potent immunomodulatory cytokine that is particularly important for modulating the tumor microenvironment and redirecting the immune response against cancer. Because IL-12 is toxic systemically, methods for producing IL-12 locally are of interest.
[0094] IL-12 is a heterodimeric cytokine encoded by two separate genes, IL-12A (p35) and IL-12B (p40). The active heterodimer (designated "p70") is formed following protein synthesis.
[0095] The NOI may encode IL-12A and / or IL-12B. The sequence of human IL-12A is available from Uniprot accession number P29459. A portion of this sequence lacking the signal peptide is shown below as SEQ ID NO:53. The sequence of human IL-12B is available from Uniprot accession number P29460. A portion of this sequence lacking the signal peptide is shown below as SEQ ID NO:54. [ka]
[0096] The NOI may encode "flexi-IL-12", a fusion between human IL-12α (p35) and IL-12β (p40) subunits joined by a linker. A suitable flexi-IL-12 sequence is shown below as SEQ ID NO:55. [ka] [ka]
[0097] In SEQ ID NO:55, the signal peptide from mouse kappa chain V-III region MOPC63 (Uniprot P01661) is shown in bold; the serine-glycine linker is underlined and in bold.
[0098] The NOI may comprise one of the sequences shown as SEQ ID NO: 53, 54 or 55, or a variant thereof. The variant sequence may have at least 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 53, 54 or 55, provided that the variant sequence retains IL-12 function when expressed in vivo. For example, the variant sequence may retain the ability to enhance the activity of cytotoxic T cells in vivo and / or the variant sequence may stimulate the production of interferon gamma (IFN-γ) by T cells.
[0099] The sequence encoding IL-12 or fliexi-IL12 can be placed downstream of a frame-slip or translational read-through motif, providing a means to control cytokine expression and reduce cytokine expression levels relative to the CAR.
[0100] The NOI may encode a chemokine, for example a chemokine that improves the efficacy of CAR-T cell therapy. The chemokine may be CCL19. In particular, the nucleic acid construct may co-express CCL19 and IL-7.
[0101] The NOI may code for an antibody or part thereof. For example, the NOI may code for an immunomodulatory antibody or antibody fragment. The antibody may block inhibitory signals (such as PD1) or activate the immune system (e.g. OX40 agonist, 41BB agonist or ICOS agonist).
[0102] The transgene may encode a toxic compound, such as a botulinum, diphtheria, or pseudomonas toxin.
[0103] Chimeric Antigen Receptor Classical chimeric antigen receptors (CARs) are chimeric type I transmembrane proteins that connect an extracellular antigen recognition domain (binder) to an intracellular signaling domain (endodomain). The binder is typically a single chain variable fragment (scFv) derived from a monoclonal antibody (mAb), but it can be based on other formats that contain an antibody-like antigen binding site. A spacer domain is usually necessary to separate the binder from the membrane and allow it to be properly oriented. A common spacer domain used is the Fc of IgG1. Depending on the antigen, more compact spacers, such as the stalk from CD8α and even only the IgG1 hinge, may be sufficient. The transmembrane domain anchors the protein to the cell membrane and connects the spacer to the endodomain.
[0104] Initial CAR designs had endodomains derived from the intracellular portion of either FcεR1 or the γ-chain of CD3ζ. As a result, these first generation receptors delivered immunological signal 1, which was sufficient to trigger T cell killing of cognate target cells, but failed to fully activate the T cell to proliferate and survive. To overcome this limitation, composite endodomains were constructed: fusion of the intracellular portion of a T cell costimulatory molecule to that of CD3ζ results in a second generation receptor that can simultaneously deliver activation and costimulatory signals after antigen recognition. The most commonly used costimulatory domain is that of CD28. This provides the most potent costimulatory signal (i.e., immunological signal 2) that triggers T cell proliferation. Several receptors containing TNF receptor family endodomains, such as the closely related OX40 and 41BB, that deliver survival signals, have also been described. Even more potent third generation CARs have now been described, with endodomains capable of delivering activation, proliferation and survival signals.
[0105] When the CAR binds to a target antigen, it results in the transmission of an activation signal to the T cell in which it is expressed. Thus, the CAR directs the specificity and cytotoxicity of the T cell toward tumor cells expressing the target antigen.
[0106] Thus, a CAR typically comprises: (i) an antigen-binding domain; (ii) a spacer; (iii) a transmembrane domain; and (iii) an intracellular domain that comprises or is associated with a signaling domain.
[0107] CAR has the general structure: Antigen-binding domain - spacer domain - transmembrane domain - intracellular signaling domain (endodomain) may have:
[0108] The NOI or combination of NOIs of the nucleic acid construct of the present invention may encode all or part of a CAR.
[0109] Functional readthrough can be utilized to increase the functionality of a CAR, which can be achieved by inserting a translational readthrough motif downstream of the antigen binding domain or between the signaling domains of the CAR (Figures 3F and F').
[0110] In some situations, it may be desirable to secrete the antigen binding domain (scFv / VHH) to mitigate the on-target off-tumor effect of CART cells targeting normal tissues that express low levels of the target antigen. The secreted antigen binding domain should bind to antigens expressed on the surface of normal cells, thereby preventing recognition of normal cells by CART cells. Functional read-through can be used to engineer T cells to secrete the antigen binding domain by placing a translational read-through motif immediately upstream of the transmembrane domain of the CAR.
[0111] Nucleic acid constructs have the general structure: scFv / VHH-TRM-spacer-TM domain-endodomain, or scFv / VHH-spacer-TRM-TM domain-endodomain (where: scFv / VHH is a nucleotide sequence encoding an antigen-binding domain, spacer is a nucleotide sequence encoding a spacer, a TM domain is a nucleotide sequence encoding a TM domain, and An endodomain is a nucleotide sequence that encodes an endodomain, which can be, for example, a first, second or third generation endodomain. may have:
[0112] Functional readthrough can also be used to generate combinations of CARs that are first, second or third generation. In this situation, a translational readthrough motif can be placed between the CD3z and co-receptor endodomains, resulting in high levels of expression of the first generation CAR (CD3ζ signaling domain only) and substantially lower levels of the second or third generation CARs. The nucleic acid construct has the general structure: scFv / VHH-spacer-TM domain-CD3ζ endodomain TRM-costimulatory domain, or scFv / VHH-spacer-TM domain-CD3ζ endodomain TRM1-costimulatory domain 1-TRM2-costimulatory domain 2 (where: scFv / VHH is a nucleotide sequence encoding an antigen-binding domain, spacer is a nucleotide sequence encoding a spacer, a TM domain is a nucleotide sequence encoding a TM domain, and CD3 zeta endodomain is a nucleotide sequence encoding the CD3 zeta endodomain, A costimulatory domain is a nucleotide sequence that encodes a costimulatory domain, such as an endodomain from a co-receptor, e.g., CD28 or a member of the TNF receptor superfamily. may have:
[0113] Because there are few CARs that have both coreceptor and CD3ζ signaling domains, different iterations can be generated by swapping the positions of the CD3ζ and coreceptor endodomains such that CAR assembly provides primarily a costimulatory signal (signal 2) and a reduced antigen signal (signal 1) to the cell.
[0114] Chimeric cytokine receptors WO 2017 / 029512 describes a chimeric cytokine receptor that grafts the binding specificity of a non-cytokine binding molecule onto the endodomain of a cytokine receptor. It also describes a chimeric transmembrane protein that includes a dimerization domain; and a cytokine receptor endodomain.
[0115] Dimerization can occur spontaneously, in which case the chimeric transmembrane protein is constitutively active, or it can occur only in the presence of a chemical dimerization inducer (CID), in which case the transmembrane protein triggers cytokine-type signaling only in the presence of the CID.
[0116] A constitutively active chimeric cytokine receptor may comprise the Fab portion of an antibody as an ectodomain. In this regard, the dimerization domain may comprise the dimerization portion of a heavy chain constant domain (CH) and a light chain constant domain (CL).
[0117] A chimeric transmembrane protein comprises two polypeptides: (i) (a) a first dimerization domain; and (b) The first chain of a cytokine receptor endodomain a first polypeptide comprising: (ii) (a) a second dimerization domain that dimerizes with the first dimerization domain; and (b) The second chain of a cytokine receptor endodomain. A second polypeptide comprising may include.
[0118] In particular, the chimeric transmembrane protein (i) (a) Heavy chain constant domain (CH) (b) The first chain of a cytokine receptor endodomain a first polypeptide comprising: (ii) (a) Light chain constant domain (CL) (b) The second chain of a cytokine receptor endodomain. A second polypeptide comprising may include.
[0119] The first and second chains of the cytokine receptor endodomain may be selected from type I cytokine receptor endodomain α, β and γ chains.
[0120] Cytokine receptor endodomains are (i) IL-2 receptor β chain endodomain (ii) the IL-7 receptor α chain endodomain; or (iii) the IL-15 receptor α chain endodomain; and / or (iv) Common γ chain receptor endodomain may include.
[0121] IL-2 IL-2 binds to the IL-2 receptor, which has three forms produced by different combinations of three different proteins often referred to as α, β, and γ "chains"; these subunits are also part of the receptors for other cytokines. The β and γ chains of the IL-2R are members of the type I cytokine receptor family.
[0122] The three receptor chains are separately and differentially expressed on various cell types and can assemble in different combinations and orders to generate low-, intermediate- and high-affinity IL-2 receptors.
[0123] The α chain binds IL-2 with low affinity, and the combination of β and γ together form a complex that binds IL-2 with intermediate affinity primarily on memory T cells and NK cells; all three receptor chains form a complex that binds IL-2 with high affinity (Kd approx. 10-11 M) on activated and regulatory T cells.
[0124] These three IL-2 receptor chains span the cell membrane and extend into the cell, delivering biochemical signals to the interior of the cell. The alpha chain is not involved in signal transduction, while the beta chain complexes with the tyrosine phosphatase JAK1. Similarly, the gamma chain complexes with another tyrosine kinase, called JAK3. These enzymes are activated by IL-2 binding to the ectodomain of the IL-2R.
[0125] When early T cells are also stimulated by antigen, IL-2 signaling promotes the differentiation of T cells into effector and memory T cells. Through their role in the generation of T cell immune memory, which depends on the expansion in number and function of antigen-selected T cell clones, they also have an important role in long-term cellular immunity.
[0126] A chimeric cytokine receptor of the present invention may comprise an IL-2 receptor β chain and / or an IL-2 receptor (ie, common) γ chain.
[0127] The amino acid sequences of the IL-2 β chain and common γ chain endodomains are shown as SEQ ID NOs:56 and 57. [ka]
[0128] The term "derived from" means that the endodomain of the chimeric cytokine receptor of the present invention has a sequence identical to the wild-type sequence of the endogenous molecule, or a variant thereof that retains the ability to complex with JAK-1 or JAK-3 and activate one of the above-mentioned signaling pathways.
[0129] A "variant" sequence has at least 80, 85, 90, 95, 98 or 99% sequence identity to a wild-type sequence (e.g., SEQ ID NO: 56 or 57), provided that the variant sequence retains the function of the wild-type sequence, i.e., the ability to complex with JAK-1 or JAK-3 and activate, for example, the JAK-STAT signaling pathway.
[0130] The percentage of identity between two polypeptide sequences can be readily determined by programs such as BLAST, which is freely available at http: / / blast.ncbi.nlm.nih.gov.
[0131] Constant Region Domain In humans, there are two types of light chains: kappa (κ) and lambda (λ). The lambda class has four subtypes: λ1, λ2, λ3 and λ4. The light chain constant region of the Fab type chimeric receptor can be derived from any of these light chain types.
[0132] The light chain constant domain of the chimeric cytokine receptor may have the sequence shown as SEQ ID NO:58, which is a kappa chain constant domain. [ka]
[0133] There are five types of mammalian immunoglobulin heavy chains: gamma, delta, alpha, mu, and epsilon, which define the classes of immunoglobulin IgG, IgD, IgA, IgM, and IgE, respectively. The gamma, delta, and alpha heavy chains have a constant domain made up of three tandem Ig domains and a hinge for added flexibility. The mu and epsilon heavy chains are made up of four domains.
[0134] The CH domain of a chimeric cytokine receptor of the invention may comprise the sequence shown as SEQ ID NO:59, which is derived from a gamma immunoglobulin heavy chain. [ka]
[0135] In a preferred embodiment, the present invention provides a nucleic acid construct comprising a first nucleotide sequence encoding a chimeric antigen receptor (CAR); a frame-slip motif (FSM) or a translational read-through motif (TRM); and a second nucleotide sequence encoding a chimeric cytokine receptor (CCR).
[0136] Cutting site The nucleic acid construct of the first aspect of the invention may include a sequence encoding a cleavage site located between the nucleic acid sequences encoding the first and second polypeptides such that the first and second polypeptides may be expressed as separate entities.
[0137] The cleavage site may be any sequence that allows the polypeptides comprising the first and second polypeptides to be separated.
[0138] Although the term "cleavage" is used herein for convenience, the cleavage site may separate the first and second polypeptides into individual entities by mechanisms other than classical cleavage. For example, for the foot and mouth disease virus (FMDV) 2A autocleavage peptide (see below), various models have been proposed to explain the "cleavage" activity: proteolysis by host cell proteinases, autoproteolysis or translational effects (Donnelly et al. (2001) J. Gen. Virol. 82:1027-1041). The exact mechanism of such "cleavage" is not important for the purposes of the present invention, as long as the cleavage site, when located between the nucleic acid sequences encoding the first and second polypeptides, allows the first and second polypeptides to be expressed as separate entities.
[0139] The cleavage site may be a furin cleavage site.
[0140] Furin is an enzyme that belongs to the subtilisin-like proprotein convertase family. Members of this family are proprotein convertases that process latent precursor proteins into their biologically active products. Furin is a calcium-dependent serine endoprotease that can efficiently cleave precursor proteins at paired basic amino acid processing sites. Examples of furin substrates include proparathyroid hormone, transforming growth factor beta 1 precursor, proalbumin, pro-beta secretase, membrane type 1 matrix metalloproteinase, pro-nerve growth factor beta subunit, and von Willebrand factor. Furin cleaves proteins immediately downstream of a basic amino acid target sequence (canonically Arg-X-(Arg / Lys)-Arg' (SEQ ID NO: 50)) and is abundant in the Golgi apparatus.
[0141] The cleavage site may be a Tobacco Etch Virus (TEV) cleavage site.
[0142] TEV protease is a highly sequence-specific cysteine protease that is a chymotrypsin-like protease. Because it is highly specific for its target cleavage site, it is frequently used for controlled cleavage of fusion proteins both in vitro and in vivo. The consensus TEV cleavage site is ENLYFQ\S (SEQ ID NO:51), where "\" indicates the peptide bond to be cleaved. Mammalian cells, such as human cells, do not express TEV protease. Thus, in embodiments in which the present nucleic acid construct contains a TEV cleavage site and is expressed in a mammalian cell, an exogenous TEV protease must also be expressed in the mammalian cell.
[0143] The cleavage site may encode a self-cleaving peptide.
[0144] "Self-cleaving peptide" refers to a polypeptide comprising a first and a second polypeptide and a peptide that functions such that once the self-cleaving peptide is produced, it is immediately "cleaved" or separated into distinct and separate first and second polypeptides without the need for any external cleavage activity.
[0145] The self-cleaving peptide may be a 2A self-cleaving peptide from an aphthovirus or a cardiovirus. The main 2A / 2B cleavage of aphthoviruses and cardioviruses is mediated by 2A "cleavage" at its own C-terminus. In aphthoviruses such as foot and mouth disease virus (FMDV) and equine rhinitis A virus, the 2A region is a short section of about 18 amino acids that, together with the N-terminal residue of protein 2B (a conserved proline residue), represents an autonomous element that can mediate "cleavage" at its own C-terminus.
[0146] The C-terminal 19 amino acids of the longer cardiovirus protein, together with the N-terminal proline of 2B, mediate "cleavage" with efficiency nearly equal to that of the aphthovirus FMDV2a sequence. Cardioviruses include encephalomyocarditis virus (EMCV) and Theiler's murine encephalitis virus (TMEV).
[0147] Mutational analysis of EMCV and FMDV2A revealed that the motif DxExNPGP (SEQ ID NO:52) is essentially responsible for the "cleavage" activity (Donelly et al. (2001) supra).
[0148] The cleavage site of the present invention has the amino acid sequence: Dx 1 Ex 2 NPGP (where x 1 and x 2 is any amino acid. 1 may be selected from the following groups: I, V, M and S. 2 may be selected from the following groups: T, M, S, L, E, Q, and F.
[0149] For example, the cleavage site may comprise one of the amino acid sequences shown in Table 2. [Table 2-1] [Table 2-2]
[0150] A cleavage site based on the 2A sequence can be, for example, 15-22 amino acids in length. The sequence can include the C-terminus of the 2A protein followed by a proline residue (corresponding to the N-terminal proline of 2B).
[0151] Mutation studies have also shown that in addition to the naturally occurring 2A sequence, several variants are also active. The cleavage site may correspond to a variant sequence from the naturally occurring 2A polypeptide that has one, two or three amino acid substitutions and that retains the ability to induce "cleavage" of a polyprotein sequence into two or more separate proteins.
[0152] Cleavage sequences may be selected from the following, all of which have been shown to be active to some extent (Donnelly et al. (2001) supra): [ka]
[0153] Based on the sequence of DxExNPGP, "motifs, "2A-like" sequences have been found in picornaviruses other than aphthoviruses or cardioviruses, "picornavirus-like" insect viruses, type C rotaviruses, and repeat sequences within Trypanosoma species and bacterial sequences (Donnelly et al. (2001) supra). The cleavage site is located within these 2A-like sequences, e.g.: [ka] [ka] may include one of the following:
[0154] The cleavage site may include a 2A-like sequence shown as SEQ ID NO:31 (RAEGRGSLLTCGDVEENPGP).
[0155] It has been shown that activity can be increased by including an N-terminal "extension" of 5 to 39 amino acids (Donnelly et al. (2001) supra). In particular, the cleavage sequence may comprise one of the following sequences, or a variant thereof having, for example, up to five amino acid changes, which retains cleavage site activity: [ka]
[0156] vector The present invention also provides a vector comprising a nucleic acid construct according to the first aspect of the invention.
[0157] Such a vector can be used to introduce the nucleic acid construct into a host cell so as to express the first and second polypeptides.
[0158] The vector may be, for example, a plasmid or a viral vector, such as a retroviral or lentiviral vector, or a transposon-based vector, or a synthetic mRNA.
[0159] The vector may be one that is capable of transfecting or transducing a mammalian cell, such as a T cell or a target cell.
[0160] cell The invention further provides a cell comprising a nucleic acid construct or vector of the invention, wherein the cell expresses the first and second polypeptides encoded by the nucleic acid sequences.
[0161] The cell can be any eukaryotic cell, for example an immunological cell.
[0162] The cell can be a cytotoxic immune cell, such as a T cell or a natural killer cell.
[0163] If the transgene expresses a target antigen, the cell can be a target cell for a T cell or a CAR-T cell.
[0164] method In a further aspect, the present invention provides a method for producing a cell according to the invention, the method comprising the step of introducing a nucleic acid construct or vector of the invention into a cell.
[0165] The nucleic acid construct may be introduced by transduction or transfection.
[0166] The cell can be a cell isolated from a subject, for example, a T cell or an NK cell isolated from a subject.
[0167] The present invention also provides a method for modulating the relative expression of two transgenes in a nucleic acid construct, comprising the step of including a frame-slip or translational read-through motif between the two transgenes to reduce expression of the downstream transgene.
[0168] The nucleic acid construct may contain a sequence encoding a cleavage site located between the two transgenes. The relative expression of the two transgenes may be adjusted by selecting different frame-slip or translational read-through motifs and / or by mutating sequences immediately 5' and / or 3' to the motifs.
[0169] The present invention also provides a method for modulating the relative expression of two transgenes in a nucleic acid construct, comprising the step of including a frame-slip or translational read-through motif between the two transgenes to reduce expression of the downstream transgene.
[0170] The frame-slip motif or translational read-through motif may be as described in the previous aspect of the invention.
[0171] The present invention will now be further illustrated by means of examples, which serve to assist those skilled in the art in practicing the invention and are not intended to limit the scope of the invention in any way. EXAMPLES
[0172] Example 1 - Preparation and testing of frame slip constructs The following constructs were transduced into SupT1 cells: ·SFGmR.RQR8-2A-SKIP_7xU-CD22ecto-CD19tm-dCD19endo SFGmR.RQR8-2A-SKIP_6xU-CD22ecto-CD19tm-dCD19endo (control)
[0173] The construct encodes RQR8, a sorting suicide transmembrane protein described in WO 2013 / 153391; and a chimeric protein having the CD22 ectodomain and the CD19 transmembrane and endodomain.
[0174] The first construct contains a transcriptional frame slip with seven thymine bases (uracil in mRNA) that promotes transcriptional slippage and loss of bases from the mRNA, which places the CD22 coding sequence in frame, resulting in expression of a CD22-CD19 chimera.
[0175] Flow cytometry analysis showed that introduction of the frame-slip motif led to a dramatic reduction in expression of the CD22-CD19 chimera, with similar levels of the RQR8 sorting selectable marker observed (Figure 2C).
[0176] Example 2 - Generation and testing of translational read-through constructs Two translational read-through motifs, STOP-CUAG and STOP-CAAUUA, were shown to be functional in human T cells (SupT1) and human B cells (Raji) and to support translational read-through of downstream self-cleaving 2A peptide sequences and transgene coding sequences (CD22 and BCMA).
[0177] To test the function of these readthrough motifs in combination with different stop codons, the following constructs were transduced into HEK293T cells: Read-through motif STOP-CUAG ·SFGmR.RQR8-STOP-TGACTAG-2A-hCD22ecto-CD19TM-dCD19endo ·SFGmR.RQR8-STOP-TAGCTAG-2A-hCD22ecto-CD19TM-dCD19endo ·SFGmR.RQR8-STOP-TAACTAG-2A-hCD22ecto-CD19TM-dCD19endo ·SFGmR.RQR8-NO_STOP_TGGCTAG-T2A-hCD22ecto-CD19TM-dCD19endo Read-through motif STOP-CAAUUA ·SFGmR.RQR8-STOP-TGACAATTA-2A-hCD22ecto-CD19TM-dCD19endo ·SFGmR.RQR8-STOP-TAGCAATTA-2A-hCD22ecto-CD19TM-dCD19endo ·SFGmR.RQR8-STOP-TAACAATTA-2A-hCD22ecto-CD19TM-dCD19endo ·SFGmR.RQR8_NO_STOP_TGGCAATTA-T2A-hCD22-CD19TM-dCD19endo Signal peptide variants SFGmR.RQR8-2A-signalK9-hCD22ecto-CD19TM-dCD19endo SFGmR.RQR8-2A-signalK10-hCD22ecto-CD19TM-dCD19endo SFGmR.RQR8-2A-signalK11-hCD22ecto-CD19TM-dCD19endo
[0178] The wild-type signal peptide sequence is shown below as SEQ ID NOs: 42-45, along with the sequences of the modified signal peptides K19, K10 and K11. SEQ ID NO:42 - Mouse Ig kappa chain V-III region signal peptide (wild type) METDTLILWVLLLLVPGSTG SEQ ID NO:43 - Mouse Ig kappa chain V-III region signal peptide (K9 variant) METDTLILKVLLLLVPGSTG SEQ ID NO:44 - Mouse Ig kappa chain V-III region signal peptide (K10 variant) METDTLILWKLLLLVPGSTG SEQ ID NO:45 - Mouse Ig kappa chain V-III region signal peptide (K11 variant) METDTLILWVKLLLVPGSTG
[0179] Expression of the CD22-CD19 chimera was analyzed by flow cytometry, and the results are shown in Figure 4A. Compared to the wild-type signal peptide, the expression of the CD22-CD19 chimera was reduced with the lysine 11 signal peptide mutant (L11K mutation). The stop-CUAG and stop-CAAUUA translational read-through motifs gave similar results when they were placed 5' to the CD22-CD19 transgene, and both motifs reduced the expression level of the chimera to approximately 2% or less than the RQR8 sortable selection marker. Lower expression levels of the CD22-CD19 chimera were obtained using the double stop translational read-through motif (line 4).
[0180] The mean fluorescence intensity of the CD22-CD19 chimera was quantified on the surface of transfected HEK293T cells, and the results are shown in Figure 4B. Using the translational read-through construct, substantially lower levels of the CD22-CD19 chimera were obtained compared to the attenuated signal peptide mutant.
[0181] Example 3 - Functional translational read-through: secretion of soluble anti-CD22 Fab As shown below, a nucleic acid construct was designed encoding an anti-CD22 CAR with an RQR8 sortable selection marker followed by a 2A self-cleaving peptide sequence and a CL and CH1 spacer region to produce a soluble Fab fragment. ·SFGmR.RQR8-2A-aCD22_FabCAR_9A8-1-STOP_SKIP_TAG-41BBz ·SFGmR.RQR8-2A-aCD22_FabCAR_9A8-1-STOP_SKIP_TAA-41BBz ·SFGmR.RQR8-2A-aCD22_FabCAR_9A8-1-STOP_SKIP_TGA-41BBz
[0182] These constructs were transduced into PBMCs and cytotoxicity assays were performed to determine the efficacy of the CARs using target cells expressing low or high levels of CD22, mimicking the situation where low levels of target antigens are expressed on normal tissues and fine tuning of the cytotoxic response is necessary to prevent targeting of these cells by CAR T cells.
[0183] Example 4 - Functional translational read-through: conversion of first to second or third generation CARs To investigate whether functional translational read-through can be used to switch conversion between first and second generation CARs, the following constructs are generated: ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-STOP_SKIP_TAA-41BB ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-STOP_SKIP_TGA-41BB ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-NO_STOP_SKIP_TCA-41BB ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-STOP_SKIP_TAG-41BB ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-STOP_SKIP_TAA-CD28 ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-STOP_SKIP_TAG-CD28 ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-NO_STOP_SKIP_TCA-CD28 ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-Zeta-STOP_SKIP_TGA-CD28
[0184] This first set of constructs expresses the sorting selection marker RQR8 and a first generation anti-CD19 CAR with an Fc spacer domain and a CD3ζ endodomain followed by a translational read-through motif and a 4-1BB or CD28 costimulatory endodomain. A restimulation assay is set up using transduced PBMCs cultured in plates coated with an anti-Fc antibody that binds to the spacer domain of the CAR and triggers proliferation. A control first generation CAR with only CD3ζ shows limited proliferation, whereas the other CARs proliferate more as a costimulatory signal is present.
[0185] Generate a second set of constructs similar to the first set of constructs, as shown below: ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-41BB-STOP_SKIP_TAA-Zeta ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-41BB-STOP_SKIP_TGA-Zeta ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-41BB-NO_STOP_SKIP_TCA-Zeta ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-41BB-STOP_SKIP_TAG-Zeta ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-CD28-STOP_SKIP_TAA-Zeta ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-CD28-STOP_SKIP_TGA-Zeta ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-CD28-NO_STOP_SKIP_TCA-Zeta ·SFGmR.RQR8-2A-aCD19fmc63-HCH2CH3pvaa-CD28-STOP_SKIP_TAG-Zeta
[0186] In these constructs, the costimulatory domain from 4-1BB or CD28 precedes the translational read-through motif and the CD3ζ endodomain is placed after it. PBMCs transduced with these constructs are used to set up cytotoxicity and proliferation assays. Translational read-through from these constructs is necessary to produce functional CARs (i.e., CARs with intracellular signaling domains).
[0187] Example 5 - Preparation and testing of composite readthrough motifs To reduce expression of multiple transgene cassettes to very low levels, a construct was designed with two STOP-translation readthrough motifs as follows: Marker (RQR8 or HA8)-STOP_ReadThrough-2A-GD3 Synthase-STOP_ReadThrough-2A-GD2 Synthase
[0188] Ganglioside GD2 is synthesized by two enzymes, GD2 synthase and GD3 synthase. The above construct results in reduced GD3 synthase expression compared to the marker gene, resulting in even lower GD2 synthase expression.
[0189] Example 6 - Preparation and testing of a universal leadthrough construct To overcome the problem of context-dependent expression from the read-through motif, a group of universal constructs can be generated into which a second transgene that is expressed at a defined level can be cloned. The universal construct consists of a self-cleaving 2A peptide sequence, followed by a stop codon and a read-through motif and a second self-cleaving peptide sequence. By flanking the stop read-through motif with the self-cleaving peptide sequence, the context-dependent effect on translational read-through is reduced, resulting in a consistent and predictable level of transgene expression.
[0190] The constructs tested were as follows: Read-through motif STOP CUAG marker-2A-transgene1-2A-UGA-CUAG-2A-transgene2 marker-2A-transgene1-2A-UAG-CUAG-2A-transgene2 · marker-2A-transgene1-2A-UAA-CUAG-2A-transgene2 Read-through motif STOP CAAUUA marker-2A-transgene1-2A-UGA-CAAUUA-2A-transgene2 marker-2A-transgene1-2A-UAG-CAAUUA-2A-transgene2 marker-2A-transgene1-2A-UAA-CAAUUA-2A-transgene2
[0191] Example 7 - Ultra-low expression by tandem arrangement of translational read-through motifs To determine whether it was possible to obtain ultra-low levels of transgene expression, constructs were generated in which two translational read-through motifs were arranged in tandem in a tricistronic cassette (Figure 5A). The first transgene in the cassette was always a cell surface marker consisting of an HA epitope displayed on a CD8a stalk for identification of transduced cells, followed by a stop codon, a translational read-through motif and a self-cleaving peptide sequence. The second transgene in the cassette was one of two fluorescent proteins, either tandem Clover3 (green fluorescent protein) or enhanced blue fluorescent protein (EBFP), followed by a stop codon, a translational read-through motif and a self-cleaving peptide sequence. The third transgene in the cassette was an alternating fluorescent protein. By arranging the stop codon and translational read-through motif in tandem, the expression level of the fluorescent protein in the third position should be lower than that in the second position.
[0192] The constructs were transduced into peripheral blood mononuclear cells (PBMCs) and flow cytometry was performed to quantify the expression levels of the fluorescent proteins relative to cell surface markers. The results of these experiments demonstrated that the expression levels of the fluorescent proteins were significantly lower when placed in the third position downstream of the two stop codons and the translational read-through motif than when placed in the second position (Figure 5B). Consistent with previous experiments, the level of translational read-through was stop codon dependent, with a hierarchical stop codon stringency of UAA>UAG>UGA. For tandem Clover3, the reduction in expression levels compared to the control without a stop codon was 33-fold for UAA, 24-fold for UAG, and 6-fold for UGA. When placed in the third position, the level of tandem Clover3 expression was reduced by more than 100-fold for all three stop codons (Figure 5C).
[0193] Example 8 - Regulation of IL-12 secretion by translational read-through IL-12 is a potent proinflammatory cytokine that is secreted by phagocytes and dendritic cells in response to signals from pathogens, T cells and natural killer (NK) cells, and components of the inflammatory extracellular matrix. The primary target of IL-12 is the cytotoxic T cell, T H 1 helper T cells and NK cells. In response to IL-12, T H 1 Helper T cells release IFNγ and TNFα.
[0194] CAR-T cells have been engineered to express IL-12 constitutively or from an inducible promoter, which has been shown to improve the efficacy of CAR-T cell therapy when targeting solid tumors. Systemic administration of IL-12 is toxic, and to circumvent this problem, CAR cells or other immune cells have been engineered to release IL-12 into the tumor microenvironment. However, transgenic T cell IL-12 secretion can result in highly toxic systemic levels of the cytokine.
[0195] We designed a construct in which flexi-IL-12, a fusion between human IL-12α (p35) and IL-12β (p40) subunits, was cloned downstream of the selection selection marker RQR8 and a self-cleaving peptide sequence. A stop codon or control sequence (UGG encoding tryptophan) and the translational read-through sequence CAAUUA were placed immediately downstream of the RQR8 coding sequence (Figure 6A). The construct was transduced into PBMCs and stained with antibodies against CD3ε and RQR8 to determine transduction efficiency and verify the presence of the transgene (Figure 6B). After determining transduction efficiency, PBMCs were returned to culture and supernatants were collected at 24, 48 and 72 hours and analyzed for the presence of IL-12 by sensitive ELISA (Figure 6C). The data demonstrated that inclusion of the stop codon and translational read-through motif reduced levels by more than 40-fold (Figure 6C). The hierarchy of stop codon stringency tended to be UAA>UAG>UGA, from most stringent to least stringent. These data demonstrated that it was possible to significantly reduce the level of IL-12 secretion from transduced cells.
[0196] To demonstrate that secreted levels of flexi-IL-12 were able to trigger an immune response, we generated another set of constructs. These were tricistronic constructs containing a suicide gene (RapaCasp9), mouse cell surface marker Thy1.1 and mouse flexi-IL-12 (Figure 7A). The mouse flexi-IL-12 sequence was located at the end of the tricistronic cassette and used a self-cleaving peptide sequence to facilitate expression of the polypeptide. A translational read-through construct (UAA-CAAUUA) was compared to a construct containing mouse flexi-IL-12 with an attenuated signal peptide sequence and another that utilizes an internal ribosome entry site (IRES) to control cytokine expression. Splenocytes obtained from BalbC mice were transduced with the constructs and flow cytometry was performed using antibodies against CD3 and cell surface marker Thy1.1 to determine transduction efficiency (Figure 7B). After determining the transduction efficiency, splenocytes were returned to culture and supernatants were collected at 24, 48 and 72 hours and analyzed for the presence of mouse IL-12 by ELISA (Figure 7C). The results demonstrated that expression of IL-12 from the IRES was reduced approximately three-fold. In contrast, expression of IL-12 from the translational read-through motif UAA-CAAUUA was reduced to the point where it was no longer detectable by ELISA (Figure 7C). To confirm whether IL-12 was present in the medium, the supernatant was collected and used to restimulate activated splenocytes. Since IFNγ is secreted by T cells and NK cells stimulated with IL-12, the supernatants from these restimulated splenocytes were analyzed for the presence of IFNγ (Figure 7D). IFNγ was detectable in all supernatants harvested from the restimulated splenocytes. Consistent with the IL-12 ELISA results, the highest levels of IFNγ secretion were observed from splenocytes restimulated with supernatants from control or IRES-transduced splenocytes. Importantly, IFNγ secretion was observed from splenocytes restimulated with supernatant from splenocytes transduced with the translational read-through construct (Figure 7D). These results demonstrated that it is possible to obtain a significant reduction in IL-12 secretion levels from transduced cells, potentially mitigating the toxic effects of this potent cytokine while maintaining therapeutic benefit.
[0197] To demonstrate the efficacy and safety profile of IL-12 secretion from a translational read-through construct in a more therapeutic context, splenocytes were co-transduced with constructs encoding truncated murine CD34, anti-GD2 chimeric antigen receptor and firefly luciferase, as well as the cytokine expression constructs described previously. Transduced splenocytes were stained with antibodies against CD34 and Thy1.1 and analyzed by flow cytometry to determine transduction efficiency (Figure 8A). 5×10 6 Mice were injected with transduced splenocytes, and 15 days later, the mice were sacrificed and their spleens were removed. Comparison of spleen size showed that splenomegaly was only observed when IL-12 was constitutively expressed (2A), whereas spleen size in the other groups was similar to that of controls (Figure 8B).
[0198] To investigate in more detail the cell types recruited to the spleens of injected mice, splenocytes were stained with antibodies against CD11b, CD3, CD4, CD8 and CD19 and analyzed by flow cytometry (Figure 9A). The results showed that the spleens of mice injected with splenocytes transduced with constitutively expressed IL-12 were dominated by macrophages (CD11b + ) were recruited, and approximately 20% of the cells were CD11b + Consistent with previous ELISA data showing that the IRES constructs yielded higher levels of IL-12 than the translational read-through constructs, there was more CD11b + In mice injected with splenocytes transduced with constructs constitutively expressing IL-12 or IRES, CD4 + and CD8 + We observed an increase in the recruitment of both CD11b and CD21 T cells in the spleens of mice injected with splenocytes transduced with the translational read-through construct (Figure 9C, D, and E). + and CD3 +The number of cells was similar to that of controls. A reduction in the number of B cells was observed only in spleens from mice injected with splenocytes that constitutively express IL-12. Taken together, these results suggested that in the absence of antigen, expression of IL-12 from a translational read-through construct did not cause any toxicity or immune cell recruitment.
[0199] All publications mentioned herein above are incorporated herein by reference.Various modifications and variations of the described methods and systems of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention.Although the present invention has been described with reference to certain preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments.Indeed, various modifications of the described modes of carrying out the invention that will be apparent to those skilled in the art of molecular biology or related fields are intended to be within the scope of the following claims.
Claims
[Claim 1] The invention described in the specification.
Citation Information
Patent Citations
Plant virus vector and plasmid and method for allowing to express foreign gene in plant
JP1993328977A
